Sociedad Americana de Hirudoterapia

Leech related Aeromonas complex infection after reconstruction with a microvascular forearm flap

Case report published in J Maxillofac Oral Surg (2016)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportSeguridad y control de infeccionesResistencia antimicrobianaBeger B et al. · Journal of maxillofacial and oral surgery, 2016

Abstract

Medical leeches (Hirudo medicinalis) in plastic and reconstructive surgery are often used for the treatment of vascular failure after microvascular surgery. Leeches are a reservoir for bacteria of the Aeromonas group that help digesting the blood meal. In some cases these bacteria are able to cause severe wound infections that can lead to loss of tissue transplants. We report about a patient with a common microvascular forearm flap after resection of an oral squamous cell carcinoma which got infected by Aeromonas spp. after treatment with medical leeches. Most of these species are resistant for common antibiotic treatment after surgery. This report shows the importance of an early concomitant antibiotic prophylaxis in the treatment of venous congestion with medical leeches.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article

Resumen

Patient with microvascular forearm flap after oral SCC resection developed Aeromonas spp infection resistant to common antibiotics after leech therapy.

Por qué esto importa para la hirudoterapia

Documents need for early concomitant antibiotic prophylaxis with medicinal leech treatment.

Citación

Leech related Aeromonas complex infection after reconstruction with a microvascular forearm flap.

Beger B et al. · Journal of maxillofacial and oral surgery, 2016

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.